Literature DB >> 6781886

Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome.

P R Bittencourt, A Richens.   

Abstract

A 22-year-old woman with the Lennox-Gastaut syndrome developed serial apnoeic-tonic seizures with concomitant bursts of repetitive spikes at 16-20/sec, after receiving therapeutic doses of chlormethiazole, clonazepam, and diazepam for the treatment of serial tonic-clonic generalized seizures. There was a direct relationship between dose of chlormethiazole and frequency of apnoeic-tonic seizures. Since these tonic seizures have been noted during natural sleep and after sleep induced by various sedative drugs in patients with slow spike-wave in EEG, it is likely that the reduction in level of consciousness induced by sedative drugs is the causative factor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6781886     DOI: 10.1111/j.1528-1157.1981.tb04339.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  5 in total

Review 1.  Medical management of Lennox-Gastaut syndrome.

Authors:  Aspasia Michoulas; Kevin Farrell
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 2.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 3.  Effects of psychotropic drugs on seizure threshold.

Authors:  Francesco Pisani; Giancarla Oteri; Cinzia Costa; Giorgio Di Raimondo; Raoul Di Perri
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide.

Authors:  Russell P Saneto; Gail D Anderson
Journal:  Ther Clin Risk Manag       Date:  2009-05-04       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.